UNITY Biotechnology Inc at UBS Global Healthcare Conference Transcript
Good afternoon, everyone. Welcome to the UBS Global Healthcare Conference. Thank you very much for joining us in person today. Very happy to have Unity Biotechnology here with us presenting and we'll open up for a fireside chat as well.
Joining us from Unity is Anirvan Ghosh, CEO. And with that, I'll turn it to you.
Thanks, Aliana. Thanks for having me here. So I thought I would just kind of provide a very brief overview of where we are and our near-term data readouts. It's a very exciting year for us as when we chatted last week, I mentioned that we were -- a number of important readouts between now and Q1 of next year. And I just want to kind of tee those up, and then we can talk about the background, science, the details of what we learned in the Phase I study and what's coming up, yes?
So this slide just provides you an overview of our therapeutic approach and the diseases we're targeting and the near-term milestones. The company is focused on developing a new
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |